Introduction {#sec1}
============

Pre-eclampsia (PE) is a pregnancy-specific syndrome characterized by *de novo* hypertension (systolic blood pressure higher than 140 mmHg and/or diastolic blood pressure higher than 90 mmHg) and/or proteinuria (\>300 mg/24 h) that occurs after 20 weeks of gestation in pregnancies, and is always accompanied with multiorgan disorders, which affects the maternal and fetal mortality and morbidity severely \[[@B1]\]. As a multifactorial disorder affecting about 5--7% of all women during pregnancy, to date, a number of studies have been carried out to explore the mechanisms of PE, including hereditary variants, inflammation, immunological imbalance and oxidative stress and so on, the specific pathogenesis has not yet been fully explained \[[@B4]\].

Although the etiology of PE is not clear, there is increasing evidence showing that inflammation plays an important role in the development of PE \[[@B7]\]. The normal pregnancy is considered to be a general inflammatory response, while PE is considered to be an enhanced inflammatory response \[[@B8]\]. In addition, PE is regarded as a complex inflammation system acting in network, which not only contains the endothelial but also including the inflammatory immune cells, blood clotting and complement system, metabolic and other changes mainly regulated by cytokines and inflammatory factors \[[@B9]\]. Otherwise, some inflammatory cytokines, such as IL-1β, IL-2, IL-6 and IFN-γ, were higher in the serum of PE patients than that of normotensive pregnancies \[[@B10]\], suggesting that inflammation may be involved in the pathogenesis of PE strongly. Oxidative stress is defined as an imbalance between reactive oxygen species (ROS) and antioxidant forces in which ROS prevails the antioxidant forces \[[@B13],[@B14]\]. Strong evidence exists that oxidative stress plays a pivotal role in the pathology of PE \[[@B15],[@B16]\].

As a stress protein, HSP70 plays a pivotal role in protecting cells against apoptosis, oxidative damage and genetic damage \[[@B17]\]. Placental ischemia, oxidative stress and maternal systemic inflammatory response, which play important roles in the pathogenesis of PE, have been shown to induce the expression of HSP70 \[[@B18]\]. Moreover, studies indicated that HSP70 is involved in the pathogenesis of hypertension and associated diseases such as coronary heart disease, atherosclerosis, ischaemic stroke, Parkinson's disease, high-altitude illness and the forth, and there were high levels of HSP70 in serum, plasma and placental tissue of PE patients \[[@B17],[@B19],[@B20]\]. As several polymorphisms in *HSP70* can influence protein expression or functions in some degree, thus may affect ability in stress tolerance and susceptibility to certain diseases \[[@B17]\]. And the gene variants involved in inflammation, oxidative stress, and thrombophilia were related to in the development in PE \[[@B21]\]. In addition, Andrea Fekete et al. found that *HSPA1L* T(2437)C polymorphisms may be associated with the susceptibility for PE \[[@B22]\]. Therefore, we designed this study to examine whether polymorphisms of three tag SNPs (rs2227956, rs1043618 and rs1061581) in *HSPA1L*, which is one of the three genes encoding HSP70 proteins \[[@B22]\], were associated with the risk of PE or not.

Materials and methods {#sec2}
=====================

Subjects {#sec2-1}
--------

About 929 PE patients as the case group and 1024 normotensive pregnencies as the control group were enrolled from the Affiliated Hospital of Qingdao University, Linyi People's Hospital, Binzhou Medical University Hospital, Yantai Yuhuangding Hospital, Yantaishan Hospital, Liaocheng People's Hospital and Heze People's Hospital between November 2017 and February 2019. The case group and the control group were age-matched and all came from Chinese Han population. Clinical characteristics such as maternal age, gestational weeks of admission and delivery, pregnancy and delivery history, clinical symptoms, and results of laboratory examinations were collected in a database through the questionnaire filled out by all the recruited staff.

The PE was diagnosed according to the criteria from the Report of the 'National High Blood Pressure Education Program' \[[@B23]\]. The recruited controls were normotensive pregnancies without clinical history of PE. In addition, both PE and control pregnant women are excluded from pre-existing hypertension, chronic hypertension, heart disease, gestational diabetes mellitus, renal disease, thyroid function disorder, uterine malformation, placental abruption, multiple pregnancies, *in vitro* fertilization treatment, cancer, or any other systemic disease, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This research was approved by the ethics committee of the Affiliated Hospital of Qingdao University and all participants in our study signed the written informed consent.

Genetic studies {#sec2-2}
---------------

We used a Qiagen DNA extraction kit (Qiagen, Hilden, Germany) to extract DNA from the 300 µl peripheral venous blood of the pregnancies and genotype the polymorphisms of rs2227956, rs1043618 and rs1061581 in HSPA1L by the TaqMan allelic discrimination real-time PCR technology with the Taqman probes and primers synthesized by Applied Biosystems of Life Technologies (New York, U.S.A.). For rs2227956, the sequence of forward and reverse primer is 5′-AATGGTATTCTCAATGTCAC AGCCA-3′ and 5′-GGACAAGAGCACCGGCAAGGTGAAC-3′ respectively; for rs1043618, the forward and reverse primer is 5′-CGTTTCCAGCCCCCAATCTCAGAGC-3′ and 5′-GAGCCGACAGAGAGCAGGGAACCGG-3′ respectively; for rs1061581, the forward primer is 5′-TCCCCAAGGTGCAGAAGCTGCTGCA-3′ and the reverse primer is 5′- GACTTCTTCAACGGGCGCGACCTGA-3′. The PCR was conducted in 25 μl reaction mixture, including 1.25 μl 20 × SNP Genotyping Assay, 12.5 μl 2 × PCR Master Mix and 11.25 μl DNA and DNase-free water. The amplifications were carried out by C1000™ thermal cycler and CFX96™ real-time system (Bio-Rad, Hercules, CA) with the following conditions: 95°C for 3 min, then 45 cycles of 95°C for 15 s and 60°C for 1 min. For each cycle, the fluorescent signals from the VIC- or FAM-labeled probes was detected. Bio-Rad CFX manager 3.0software was used to conduct the genotyping.

Statistical analysis {#sec2-3}
--------------------

All analyses were conducted by statistical software package SPSS 21.0 (SPSS Inc., Chicago, IL, U.S.A.). In order to value whether the control group was representative, we use the chi-square test to assess Hardy--Weinberg equilibrium (HWE) in the controls. Student's *t*-test was used to compare differences between cases and controls in demographic and clinical characteristics. Statistical significance was set at *P* \< 0.05 (two-sided). We used Pearson's χ2 test (if expected values were below 5, Fisher's exact test was used) to compare differences in allelic and genotypic distributions between two groups and a significance threshold of *P* = 0.016 (*P*~0~/*N, P*~0~ = 0.05, *N* = 3 SNPs) (two sided) was required when a formal Bonferroni's correction for the number of SNPs was analyzed. The relative risk degree was showed by odds ratios (ORs) and 95% confidence intervals (CIs).

Result {#sec3}
======

Demographic and clinical characteristics {#sec3-1}
----------------------------------------

[Table 1](#T1){ref-type="table"} showed the comparison in demographic and clinical characteristics between cases and controls. The mean age of cases and controls was 30.33 ± 5.29 and 30.55 ± 4.14 years old respectively, which was matched between both groups. Compared with the healthy pregnant women, the PE patients have earlier gestational weeks at admission (35.31 ± 3.68 weeks vs. 39.02 ± 1.56 weeks, *P* \< 0.001), gestational weeks at delivery (36.13 ± 3.26 weeks vs. 39.35 ± 1.29 weeks, *P* \< 0.001), lower birth weight of offspring (2579.12 ± 953.79 g vs. 3411.18 ± 366.16 g, *P* \< 0.001), higher Systolic blood pressure (P \< 0.001) and Diastolic blood pressure (P \< 0.001), and higher levels of Urea nitrogen (*P* \< 0.001), Creatinine (*P* \< 0.001), ALT (*P* \< 0.001), and AST (*P* \< 0.001). However, no significant differences were found between the cases and controls in time of pregnancies, number of abortions, white blood cell, neutrophil, triglycerides and total cholesterol.

###### Clinical characteristics

                                         Cases              Controls           *t*       *P*-value
  -------------------------------------- ------------------ ------------------ --------- --------------
  Age (years)                            30.33 ± 5.29       30.55 ± 4.14       −1.011    0.312
  Gestational age at admission (weeks)   35.31 ± 3.68       39.02 ± 1.56       −28.302   *P* \< 0.001
  Gestational age at delivery (weeks)    36.13 ± 3.26       39.35 ± 1.29       −27.365   *P* \< 0.001
  Time of pregnancy                      2.18 ± 1.23        2.22 ± 1.21        −0.81     0.418
  Number of abortion                     0.60 ± 0.93        0.68 ± 0.90        −1.908    0.057
  Birth weight of offspring (g)          2579.12 ± 953.79   3411.18 ± 366.16   −24.257   *P* \< 0.001
  Systolic blood pressure (mmHg)         159.39 ± 19.09     114.26 ± 10.02     65.606    *P* \< 0.001
  Diastolic blood pressure (mmHg)        103.31 ± 13.59     73.78 ± 7.98       58.648    *P* \< 0.001
  Urea nitrogen (mmol/l)                 4.65 ± 2.05        3.45 ± 3.26        9.074     *P* \< 0.001
  Creatinine (µmol/l)                    67.68 ± 27.07      55.55 ± 15.27      11.029    *P* \< 0.001
  ALT(IU/l)                              24.68 ± 45.89      15.03 ± 13.76      5.674     *P* \< 0.001
  AST(IU/l)                              28.77 ± 47.89      19.45 ± 13.29      5.268     *P* \< 0.001

Genotypic and allelic frequencies {#sec3-2}
---------------------------------

[Table 2](#T2){ref-type="table"} showed the genotypic and allelic frequencies of the *HSPA1L* rs2227956, rs1043618 and rs1061581 in cases and controls. The participants of control group in our study were in accordance with HWE for the three SNPs suggesting that they had a group representative (rs2227956, χ2 = 3.076, *P* = 0.0794; rs1043618, χ2 = 2.277, *P* = 0.1313; rs1061581, χ2 = 3.828, *P* = 0.0504). For the PE patients and healthy pregnant women, we found a significant difference in genotypic and allelic frequencies of *HSPA1L* rs1061581 polymorphism (χ2 = 29.863, *P* \< 0.001 by genotype; χ2 = 27.298, *P* \< 0.001, OR = 1.874, 95%CI 1.476--2.379 by allele), and *HSPA1L* rs1061581 A alleles occurred more frequently in PE patients compared with healthy controls (PE vs. controls 10.28% vs. 5.76%). However, no statistical significances were observed for rs2227956 and rs1043618 between the two groups in terms of genotypic frequencies (rs2227956, χ2 = 0.396, *P* = 0.82; rs1043618, χ2 = 0.731, *P* = 0.694), nor for allelic frequencies (rs2227956, χ2 = 0.009, *P* = 0.924, OR = 0.993, 95%CI 0.850--1.159; rs1043618, χ2 = 0.103, *P* = 0.748, OR = 1.022, 95%CI 0.896--1.164).

###### The genotypic and allelic frequencies of rs2227956、rs1043618 and rs1061581 in cases and controls

                     Rs2227956   Rs1043618   Rs1061581                                                                                                        
  ----------- ------ ----------- ----------- ----------- -------------- ------ ------- ----- ----- -------------- ------ --------- ----- ----- -------------- ------
  PE          929    53          \`280       596         386            1472   141     394   394   676            1182   0         191   738   191            1667
  Control     1024   54          320         650         428            1620   143     449   432   735            1313   0         118   906   118            1930
  χ^2^               0.396                               0.009                 0.731               0.103                 29.863                27.298         
  *P*-value          0.82                                0.924                 0.694               0.748                 \<0.001               \<0.001        
  OR                                                     0.993                                     1.022                                       1.874          
  95%CI                                                  0.850--1.159                              0.896--1.164                                1.476--2.379   

In order to further explore the relationship between the polymorphisms of *HSPA1L* and PE, we divided the PE patients into early-onset PE and late-onset PE according to the gestational age at diagnosis (early-onset PE defined as those diagnosed before the 34th week of gestation, known to be more severely affected than those with late-onset PE \[[@B24]\]). Through analyzing the [Table 3](#T3){ref-type="table"}, we can find significant differences in genotypic and allelic frequencies of *HSPA1L* rs1061581 polymorphism between early-onset /late-onset PE and controls (early-onset PE vs. controls: χ2 = 26.134, *P* \< 0.001 by genotype; χ2 = 24.073, *P* \< 0.001, OR = 2.003, 95%CI 1.511--2.655 by allele; late-onset PE vs. controls: χ2 = 14.009, *P* \< 0.001 by genotype; χ2 = 12.966, *P* \< 0.001, OR = 1.669, 95%CI 1.260--2.211 by allele). *HSPA1L* rs1061581 A alleles occurred more frequently in early-onset PE and late-onset PE than controls respectively (early-onset PE vs. controls:10.91% vs. 5.76%, late-onset PE vs. controls: 9.26% vs. 5.76%). Nevertheless, no statistical differences in genotypic and allelic frequencies were found between early-onset /late -onset PE and controls in rs2227956 and rs1043618.

###### The comparison of genotype distributions and allelic frequencies between early/late-onset PE and control groups

                          Rs2227956   Rs1043618   Rs1061581                                                                                                   
  ---------------- ------ ----------- ----------- ------------- ------- ------ ------------- ----- ----- ------------- ------ --------- ----- ----- --------- ------
  Early-onset PE   440    26          126         288           178     702    68            195   177   331           549    0         96    344   96        784
  Control          1024   54          320         650           428     1620   143           449   432   735           1313   0         118   906   118       1930
  χ^2^                    1.106                                 0.169          0.774                     0.791                26.134                24.073    
  *P*-value               0.575                                 0.681          0.679                     0.374                \<0.001               \<0.001   
  OR                                                            0.960                                    1.077                                      2.003     
  95%CI                                           0.789-1.168                  0.915-1.268               1.511-2.655                                          
  Late-onset PE    513    29          163         321           221     805    76            210   227   362           664    0         95    418   95        931
  Control          1024   54          320         650           428     1620   143           449   432   735           1313   0         118   906   118       1930
  χ^2^                    0.165                                 0.169          1.188                     0.109                14.009                12.966    
  *P*-value               0.921                                 0.681          0.552                     0.741                \<0.001               \<0.001   
  OR                                                            1.039                                    0.974                                      1.669     
  95%CI                                           0.865−1.248                  0.833-1.139               1.260−2.211                                          

Moreover, based on guidelines from the American College of Obstetricians and Gynecologists, we divided PE patients into mild and severe PE groups so that we can further explore the association between the polymorphisms of *HSPA1L* and PE \[[@B25]\]. [Table 4](#T4){ref-type="table"} displays the analyzed results in detail. There were significant differences in genotypic and allelic frequencies of *HSPA1L* rs1061581 polymorphisms between mild/severe PE and controls (mild PE vs. controls: χ2 = 16.200, *P* \< 0.001 by genotype; χ2 = 15.046, *P* \< 0.001, OR = 1.997, 95%CI 1.400--2.849 by allele; severe PE vs. controls: χ2 = 22.111, *P* \< 0.001 by genotype; χ2 = 20.335, *P* \< 0.001, OR = 1.786, 95%CI 1.384--2.305 by allele). *HSPA1L* rs1061581 A alleles occurred more frequently in mild PE and severe PE than controls respectively (mild PE vs. controls: 10.88% vs. 5.76%, severe PE vs. controls: 9.85% vs. 5.76%). However, we failed to find significant differences in the genotypic and allelic frequencies of rs2227956 and rs1043618 between mild/severe PE and controls.

###### The comparison of genotype distributions and allelic frequencies between mild/severe PE and control groups

                     Rs2227956   Rs1043618   Rs1061581                                                                                                        
  ----------- ------ ----------- ----------- ------------- ------- ------ ------------- ------- ----- ------------- ------ --------- -------- ----- --------- ------
  Mild PE     216    14          70          132           98      334    31            82      103   144           288    0         47       169   47        385
  Control     1024   54          320         650           428     1620   143           449     432   735           1313   0         118      906   118       1930
  χ^2^               0.709       0.682                     2.711                        1.018         16.200                         15.046                   
  *P*-value          0.702                                 0.409          0.258                       0.313                \<0.001                  \<0.001   
  OR                                                       1.111                                      0.893                                         1.997     
  95%CI                                      0.866−1.425                  0.717−1.112                 1.400−2.849                                             
  Severe PE   711    40          209         462           289     1133   110           309     292   529           893    0         140      571   140       1282
  Control     1024   54          320         650           428     1620   143           449     432   735           1313   0         118      906   118       1930
  χ^2^               0.717                                 0.169          0.793                       0.624                22.111                   20.335    
  *P*-value          0.699                                 0.681          0.673                       0.429                \<0.001                  \<0.001   
  OR                                                       0.965                                      1.058                                         1.786     
  95%CI                                      0.817−1.141                  0.92−1.218                  1.384−2.305                                             

Discussion {#sec4}
==========

PE is a common systemic obstetric disorder whose specific pathogenesis has not yet been fully explained. However, it is becoming increasingly accepted that oxidative stress, and maternal systemic inflammatory response have a key role in the pathogenesis of PE \[[@B8],[@B15],[@B16]\], which may induce the expression of HSP70 \[[@B18]\].

Heat shock proteins (HSPs) are highly conserved molecules that range from 10 to 150 kDa in molecular mass and function as major molecular chaperones responding to a variety of stress stimuli and maintaining protein homeostasis \[[@B26]\] and are found in all major cellular compartments. Up to now, three major families of HSPs have been revealed: low molecular mass HSPs (16−47 kDa), HSP70 (68−73 kDa), HSP90 (85−90 kDa) \[[@B27]\]. As one of the major HSPs, HSP70 is essential for a cell's machinery and involved in varieties processes including protein folding, mediating cytoprotective, antiapoptotic effects and regulating immune response \[[@B28]\]. Recent studies have demonstrated that the expression of HSP70 increased in cerebral, myocardial and renal ischemia \[[@B29]\]. Furthermore, HSP70 was related to the pathogenesis of hypertension and associated diseases \[[@B17],[@B19]\] and there were high levels of HSP70 in serum, plasma and placental tissue of PE patients \[[@B20]\].

Molvarec et al. denote that elevated levels of circulating HSP70 in PE patients may indicate oxidative stress, systemic inflammation and hepatocellular injury, which not only might play an important role in the pathogenesis of PE, but also could be a pivotal marker for the pathogenesis of PE \[[@B32]\]. Furthermore, when incubating with HSP70, human monocytes presented a rapid intracellular calcium flux, activated nuclear factor-kB (NF-kB), and up-regulated the expression of proinflammatory cytokines \[[@B33]\]. And several studies demonstrated increased NF-kB activation in pregnancies with PE \[[@B34]\]. Therefore, we may conclude that NF-kB signaling is one of pathways that elevated levels of circulating HSP70 participate in the pathogenesis of PE. NF-kB is a hetero- or homo-dimer that consists of five subunits of the Rel family of polypeptides: NF-kB1 (p50/p105), NFkB2 (p52/p100), RelA (p65), c-Rel and RelB. It mainly exists in the form of the heterodimer p65/p50 \[[@B37]\]. Before activation, most NF-kB molecules are located in the cytoplasm bounding to a inhibitor of NF-kB protein (IkB). When stimulated, e.g. by HSP70, inflammatory cytokines or ROS, the IkB kinase (IKK) complex is activated, which allows NF-kB to release from the IkB and to translocate to the nucleus. After arriving in the nucleus, NF-kB will bind to kB-regulatory elements of DNA and coordinate transcription activation of plentiful genes involved in vascular inflammation, such as adhesion molecules, chemokines and cytokines, which are highly associated with endothelial dysfunction and the pathogenesis of PE \[[@B37],[@B38]\].

A previous study indicated that the heat shock transcriptional regulatory factors of genetically hypertensive animals were enhanced in activation which coupled to polymorphisms of *HSP70* \[[@B39],[@B40]\]. In humans, three genes encode members of the HSP70 class: *HSPA1A, HSPA1B* and *HSPA1L* localized on chromosome 6p21.3 \[[@B22]\]. *HSPA1A* and *HSPA1B* encode identical heat shock-inducible protein products, whereas the *HSPA1L* encodes a non-heat inducible protein that shares 90% sequence identity with the heat shock-inducible protein products \[[@B41]\]. Andrea Fekete et al. found that *HSPA1L* (2437)CC genotypes were more frequent among PE patients than controls, suggesting that *HSPA1L* T(2437)C polymorphisms may be related with the susceptibility for PE \[[@B22]\]. Therefore, we chosen three tag SNPs (rs2227956, rs1043618 and rs1061581) in *HSPA1L* gene and conducted genotyping and analyzing to investigate the relationship between polymorphisms of the three SNPs in *HSPA1L* and the susceptibility for PE.

In the present study, we observed significant differences in genotypic and allelic frequencies of rs1061581 between the PE patients and the normotensive pregnancies, which can demonstrate an association between *HSPA1L* rs1061581 polymorphism and the susceptibility for PE. Moreover, *HSPA1L* rs1061581 A alleles occurred more frequently in PE patients compared with healthy controls (PE vs. controls 10.28% vs. 5.76%), suggesting that *HSPA1L* rs1061581 A alleles may play a role in the susceptibility for PE. However, we failed to reveal an association between the polymorphisms of other two SNPs and PE. Furthermore, the polymorphism of *HSPA1L* rs1061581 was found to be associated with early-onset PE, late-onset PE, mild PE and severe PE respectively and *HSPA1L* rs1061581 A alleles were more frequent in early-onset PE, late-onset PE, mild PE and severe PE than controls respectively, indicating that *HSPA1L* rs1061581 A alleles may play a role in the susceptibility for PE further. Whereas, for rs2227956 and rs1043618, there were no significant association between the polymorphisms and early-onset /late-onset /mild /severe PE, neither. Therefore, it can be concluded that the present study provides apparent evidence that polymorphism of *HSPA1L* rs1061581 is associated with the risk of PE in Han Chinese women. However, larger-scale and well-designed studies involving different races and regions with environmental analyses are necessary to be performed to confirm our findings and further investigate the pathogenesis of PE.
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